CN110520161A - 用于癌症选择性标记和靶向的触发器可激活的糖缀合物 - Google Patents

用于癌症选择性标记和靶向的触发器可激活的糖缀合物 Download PDF

Info

Publication number
CN110520161A
CN110520161A CN201880023821.3A CN201880023821A CN110520161A CN 110520161 A CN110520161 A CN 110520161A CN 201880023821 A CN201880023821 A CN 201880023821A CN 110520161 A CN110520161 A CN 110520161A
Authority
CN
China
Prior art keywords
compound according
compound
alkyl
amino
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880023821.3A
Other languages
English (en)
Chinese (zh)
Inventor
程建军
蔡恺珉
于晋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN110520161A publication Critical patent/CN110520161A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880023821.3A 2017-02-10 2018-02-12 用于癌症选择性标记和靶向的触发器可激活的糖缀合物 Pending CN110520161A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457597P 2017-02-10 2017-02-10
US62/457597 2017-02-10
PCT/US2018/017802 WO2018148650A1 (en) 2017-02-10 2018-02-12 Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Publications (1)

Publication Number Publication Date
CN110520161A true CN110520161A (zh) 2019-11-29

Family

ID=63107851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880023821.3A Pending CN110520161A (zh) 2017-02-10 2018-02-12 用于癌症选择性标记和靶向的触发器可激活的糖缀合物

Country Status (6)

Country Link
US (1) US11299509B2 (enExample)
EP (1) EP3595729A4 (enExample)
JP (1) JP2020507584A (enExample)
KR (1) KR20190126314A (enExample)
CN (1) CN110520161A (enExample)
WO (1) WO2018148650A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161452A1 (zh) * 2021-01-28 2022-08-04 南京桦冠生物技术有限公司 缀合物及其用途
WO2023078464A1 (zh) * 2021-11-08 2023-05-11 上海弼领生物技术有限公司 一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用
CN116655715A (zh) * 2023-07-27 2023-08-29 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
WO2020061129A1 (en) * 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2021024256A1 (en) * 2019-08-05 2021-02-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Anticancer agents
WO2021155297A1 (en) * 2020-01-29 2021-08-05 President And Fellows Of Harvard College Methods for labeling and targeting cells
CN120380004A (zh) * 2022-12-08 2025-07-25 杭州瑞奥生物医药有限公司 单糖、药物组合物及诊断和治疗应用
CN116239640B (zh) * 2023-01-19 2024-03-08 中国药科大学 吉西他滨前药及其医药用途
WO2025036407A1 (en) * 2023-08-15 2025-02-20 Surio Therapeutics Co. Ltd. Aldh-activable funtionalized monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications
CN118603851A (zh) * 2024-05-22 2024-09-06 杭州瑞奥生物医药有限公司 一种检测细胞表面叠氮的两步法荧光标记流式方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1102785T3 (da) * 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP2877480B1 (en) 2012-06-28 2017-09-06 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
EP3912642B1 (en) 2012-10-23 2023-04-12 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
US9943624B2 (en) 2012-11-30 2018-04-17 University Of Massachusetts Multi-functional surface coating of implants
RU2015129800A (ru) * 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
US9695189B2 (en) * 2013-03-01 2017-07-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
ES2658039T3 (es) * 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015021305A1 (en) 2013-08-09 2015-02-12 The Research Foundation For The State Univeristy Of New York Cancer cell specific imaging probes and methods of use
EP3125943A4 (en) * 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
KR20230144660A (ko) 2014-12-04 2023-10-16 셀진 코포레이션 생체분자 컨쥬게이트
EP3892305A1 (en) * 2015-01-30 2021-10-13 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy
CN108699095B (zh) * 2015-10-07 2022-05-13 伊利诺伊大学评议会 用于癌症选择性标记和靶向的触发子可活化代谢糖前体
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161452A1 (zh) * 2021-01-28 2022-08-04 南京桦冠生物技术有限公司 缀合物及其用途
WO2023078464A1 (zh) * 2021-11-08 2023-05-11 上海弼领生物技术有限公司 一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用
CN116655715A (zh) * 2023-07-27 2023-08-29 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途

Also Published As

Publication number Publication date
WO2018148650A1 (en) 2018-08-16
US20190367550A1 (en) 2019-12-05
US11299509B2 (en) 2022-04-12
JP2020507584A (ja) 2020-03-12
EP3595729A1 (en) 2020-01-22
KR20190126314A (ko) 2019-11-11
EP3595729A4 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
CN110520161A (zh) 用于癌症选择性标记和靶向的触发器可激活的糖缀合物
CN108699095B (zh) 用于癌症选择性标记和靶向的触发子可活化代谢糖前体
CA2799773C (fr) Nouveaux bras autoreactifs et prodrogues les comprenant
CA2695297C (en) Substituted cc-1065 analogs and their conjugates
RU2730502C2 (ru) Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры
JP2023119064A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
CN114555610A (zh) 硼酸酯前药及其用途
JP2001501596A (ja) バイオコンジュゲートおよび生物学的活性剤の送達
HUE035798T2 (en) CC-1065 analogues and conjugates
CN105407920A (zh) 靶向癌症、尤其是前列腺癌的合成性抗体模拟化合物(SyAMs)
JP2002516878A (ja) テキサフィリン結合体およびその使用
JP2022537543A (ja) 高速で且つ効率的なクリック放出の為の化合物
WO2021114864A1 (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
CN106572991A (zh) 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物
RS62412B1 (sr) Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka
JP2012530688A (ja) 酸に不安定なトリガーユニット
US11591357B2 (en) Payload and linker designs for platinum-acridine anticancer agents and methods thereof
CN113365969A (zh) 含有邻苯二甲醛的连接体及其用于制备抗体-药物缀合物的用途
CN113321698B (zh) 一种单甲基澳瑞他汀e前药及其制备方法和应用
US20250170265A1 (en) Diazonium compounds and methods of use for dna cleavage
Wang et al. Synthesis and cytotoxicity of a biotinylated CC-1065 analogue
KR20250174687A (ko) 세포독성제를 전달하기 위한 항체-약물 접합체
Cartwright The design and synthesis of duocarmycin-based conjugates for targeted delivery to tumours
HK40079820B (zh) 含叔胺药物物质的靶向递送
HK40074614A (en) Boronic ester prodrugs and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191129